無(wú)形體免疫熒光玻片

Anaplasma slides

廣州健侖生物科技有限公司

包括包柔氏螺旋體菌、布魯氏菌、貝納特氏立克次體、土倫桿菌、鉤端螺旋體、新型立克次體、恙蟲(chóng)病、立克次體、果氏巴貝西蟲(chóng)、馬焦蟲(chóng)、牛焦蟲(chóng)、利什曼蟲(chóng)、新包蟲(chóng)、弓形蟲(chóng)、貓流感病毒、貓冠狀病毒、貓皰疹病毒、犬瘟病毒、犬細(xì)小病毒等病原微生物的 IFA、MIF、ELISA試劑。

無(wú)形體免疫熒光玻片

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無(wú)形體、蜱蟲(chóng)、恙蟲(chóng)、利什曼原蟲(chóng)、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲(chóng)病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-3室
【企業(yè)文化】

乍看之下，Davies似乎不像“癌癥戰(zhàn)爭(zhēng)”中的戰(zhàn)士，他是物理學(xué)出身，而非生物醫(yī)學(xué)。但是，大約7年前，他被邀請(qǐng)?jiān)趤喞Ｄ侵萁⒁粋€(gè)新機(jī)構(gòu)——由國(guó)立癌癥研究所資助的12所機(jī)構(gòu)中的1個(gè)，以便將物理學(xué)家和腫瘤學(xué)家聯(lián)合在一起，發(fā)現(xiàn)該疾病的新視角。“我們被要求從上到下重新思考癌癥。”Davies說(shuō)。
隨后，Davies與澳大利亞國(guó)立大學(xué)天體生物學(xué)家Charley Lineweaver和英國(guó)倫敦健康科學(xué)中心腫瘤學(xué)家Mark Vincent展開(kāi)合作，提出了“返祖現(xiàn)象”模式，將癌癥定位為古老“預(yù)編”特性的重新表達(dá)。在上個(gè)月發(fā)表于《生物學(xué)論文集》的新研究中，該研究小組指出，因?yàn)榘┌Y出現(xiàn)在許多動(dòng)物、植物和人類中，那么它必須從億萬(wàn)年前開(kāi)始進(jìn)化，那時(shí)生物擁有共同的單細(xì)胞祖先。
在那時(shí)，細(xì)胞受益于永生，或無(wú)限增殖能力，正如癌癥那樣。但當(dāng)復(fù)雜的多細(xì)胞生物開(kāi)始出現(xiàn)，“‘永生’被轉(zhuǎn)包給卵子和抗原抗體。”Davies說(shuō)，不涉及繁衍的體細(xì)胞不再需要這種機(jī)能。
該研究小組提出的假設(shè)是，當(dāng)健康細(xì)胞面臨環(huán)境威脅時(shí)，例如輻射或生活因素，細(xì)胞能夠回復(fù)到“預(yù)編的安全模式”。這樣一來(lái)，細(xì)胞會(huì)拋棄更高的機(jī)能，并將它們的休眠能力切換至增殖能力，以便存活下來(lái)。“癌癥是一種自動(dòng)防障功能，”Davies提到，“一旦這個(gè)子程序被觸發(fā)，就會(huì)冷酷地運(yùn)行該程序。”
9月11日，在英國(guó)帝國(guó)理工學(xué)院舉辦的一個(gè)醫(yī)學(xué)工程會(huì)議上，Davies描述了一系列基于這種返祖現(xiàn)象的癌癥療法。Davies指出，與簡(jiǎn)單地攻擊癌癥復(fù)制能力不同，該模型揭示了“癌癥的阿喀琉斯之踵”。例如，如果該理論正確，那么癌癥進(jìn)化初期地球的環(huán)境更酸且氧氣更稀薄。因此，研究人員預(yù)測(cè)，利用高水平氧氣和在飲食中加入還原糖以降低酸性，能夠抑制腫瘤并引起腫瘤收縮。

At first glance, Davies does not seem like a warrior in the "cancer war", he is a physics background, rather than biomedical. However, about seven years ago he was invited to establish a new agency in Arizona, one of 12 institutions funded by the National Cancer Institute, to bring together physicists and oncologists to discover the disease New perspective. "We were asked to rethink the cancer from top to bottom," Davies said.
Davies then collaborated with astrobiologist Charley Lineweaver of the Australian National University and Mark Vincent, an oncologist at the London Health Science Center in the UK, to propose a "return to ancestor phenomenon" model that positions cancer as a re-expression of the ancient "pre-programmed" nature. In a new study published in the Proceedings of Biology last month, the team pointed out that because cancer appears in many animals, plants and humans, it must evolve hundreds of millions of years ago when the creatures have common Single cell ancestor.
At that time, cells benefit from eternal life, or infinite proliferative capacity, just as cancer does. But when complex multicellular organisms begin to emerge, "Immortality" is subcontracted to the egg and antigenic antibodies, Davies said, not involving multiplying somatic cells that are no longer needed for this function.
The team's hypothesis is that when healthy cells are exposed to environmental threats, such as radiation or life, cells can revert to a "pre-programmed security model." As a result, cells discard higher functions and switch their dormancy to proliferative capacity in order to survive. "Cancer is an automatic barrier," Davies said. "Once the subroutine is triggered, it runs coldly."
On September 11, at a medical engineering conference organized by Imperial College London, Davies described a series of cancer therapies based on this anteversion phenomenon. Davies points out that unlike a simple attack on cancer replication, the model reveals "the Achilles heel of cancer." For example, if the theory is correct, the Earth's environment is more acidic and oxygenier at the beginning of cancer's evolution. Therefore, the researchers predicted that the use of high levels of oxygen and added to the diet reducing sugar to reduce acidity, can inhibit the tumor and cause tumor shrinkage.